Ira Braverman, MD
Geriatric Medicine · National City, CANPI 1124039755
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,833 of the $5,521 with a category attached, or 87.5%. It is spread thinly across 41 manufacturers, the largest accounting for just 8.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,954 and has fallen 82.6% since, to $339 in 2025. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$487
- Sunovion Pharmaceuticals Inc.$432
- Sanofi-aventis U.S. LLC$373
- AbbVie$369
- Sanofi US Services Inc.$325
- Novartis$322
- plus $3K from 35 others
What the payments were for
- Speaking & faculty fees$62511%
- Food & beverage$4,83388%
- Education$621%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,521 in reported general payments places this provider in the 90th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 128 | $155,180 |
| TrulicityDulaglutide | 73 | $142,800 |
| EliquisApixaban | 137 | $137,859 |
| OzempicSemaglutide | 126 | $136,865 |
| JanuviaSitagliptin Phosphate | 66 | $72,333 |
| MounjaroTirzepatide | 63 | $71,764 |
| OxycontinOxycodone Hcl | 13 | $34,210 |
| FarxigaDapagliflozin Propanediol | 20 | $29,244 |
| LinzessLinaclotide | 34 | $27,666 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $26,611 |
| TradjentaLinagliptin | 31 | $24,820 |
| XareltoRivaroxaban | 17 | $15,511 |
| Humulin R U-500Insulin Regular, Human | 11 | $14,816 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $13,621 |
| Atorvastatin Calcium | 1,084 | $11,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $487 | $214,565136 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $142 | $188,094172 claims |
| PfizerEliquis | $263 | $137,859137 claims |
| Novo NordiskOzempic | $287 | $136,865126 claims |
| MerckJanuvia, Janumet | $120 | $98,94491 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $231 | $59,56473 claims |
| AbbVieLinzess | $369 | $27,66634 claims |
| Johnson & JohnsonXarelto | $159 | $15,51117 claims |
| GSKBreo Ellipta | $225 | $8,66116 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $54 | $3,95334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in National City
- Troy NiguidulaNational City$4K
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.